New England Biolabs® Launches Next Generation HiScribe ™ In Vitro Transcription Kit, Incorporating CleanCap® Technology from TriLink® Biotechnologies for mRNA Synthesis

0

IPSWICH, Mass., Nov.8, 2021 / PRNewswire / – New England Biolabs (NEB®) today announced the release of a kit for the generation of in vitro Synthetic mRNA transcribed capped using TriLink Biotechnologies, part of Maravai LifeSciences (NASDAQ: MRVI), CleanCap Reagent AG.

NEB HiScribe Portfolio in vitro Transcription Kits (IVT) are designed to simplify workflows while producing high yields of RNA. New HiScribe T7 mRNA Kit with CleanCap Reagent AG produces high yield of mRNA with Cap 1 structure in one step for research and preclinical workflows. Messenger RNAs with Cap 1 structures are desirable for increased biological activity and reduced immunogenicity. As manufacturing scales increase, in vitro transcription kits, reagents and enzymes can be obtained in large quantities, including GMP * grade, allowing a seamless transition to large-scale therapeutic mRNA manufacturing, including vaccine production.

“Over the past year and a half, the use of synthetic mRNA vaccines has proven the effectiveness of mRNA as a therapeutic modality,” said Ted Davis, executive director of business and product development at NEB . “The new HiScribe T7 mRNA kit with CleanCap Reagent AG combines NEB’s in-depth enzymological expertise with TriLink’s new CleanCap technology, enabling research and development to accelerate by enabling scientists to easily generate mRNAs from high quality and quickly screen many different molecules or designs.

“TriLink is proud to be included in the next generation of NEBsin vitrotranscription kits, ”said Brian Neel, COO of TriLink Biotechnologies. “The inclusion of our CleanCap Reagent AG is a critical step in the spread of CleanCap, making it even easier for scientists to generate superior performing mRNA, with 1 structure, in a single pot reaction than ever before. The HiScribe platform is a perfect complement to CleanCap technology. ”

TriLink’s headquarters in San Diego CA has expanded to enable TriLink to meet the global demand for the CleanCap reagent and supports multiple COVID-19 vaccine programs around the world. TriLink has also recently expanded its nucleoside triphosphate manufacturing capabilities, as well as contract development and manufacturing organization services, which now include the manufacture of plasmid DNA for mRNA-based therapies and the production of vaccines.

More information about the HiScribe T7 mRNA Kit with CleanCap Reagent AG can be found at www.neb.com/E2080.

For more information on NEB’s GMP Grade IVT Reagent Line, visit www.neb.com/GMP

More information on TriLink’s CleanCap reagent can be found at https://www.trilinkbiotech.com/cleancap/

* “GMP-grade” is a trademark term used by NEB to describe reagents manufactured at our Rowley, MA facility, where we use procedures and process controls to manufacture reagents under more stringent conditions in order to achieve more stringent product specifications and in accordance with ISO 9001. and ISO 13485 quality management system standards. NEB does not manufacture or sell products known as active pharmaceutical ingredients (APIs), and does not also does not manufacture products that comply with all current Good Manufacturing Practice regulations.

About New England BiolabsFounded in the mid-1970s, New England Biolabs, Inc. is the industry leader in the discovery and production of enzymes for molecular biology applications and now offers the largest selection of recombinant and native enzymes for production. genomic research. NEB continues to expand its product offering in areas related to PCR, gene expression, sample preparation for next generation sequencing, synthetic biology, glycobiology, epigenetics and to RNA analysis. In addition, NEB is focused on strengthening alliances that allow new technologies to reach key market sectors, including the development of molecular diagnostics, as well as nucleic acid vaccines. New England Biolabs is privately held, headquartered in Ipswich, MA, USA, and has extensive global distribution through a network of exclusive distributors, agents and eight subsidiaries located in Australia , Canada, China, France, Germany, Japan, Singapore and Great Britain. For more information on New England Biolabs, visit www.neb.com.

NEW ENGLAND BIOLABS® and NEB® are registered trademarks of New England Biolabs, Inc.

About TriLink Biotechnologies TriLink Biotechnologies, part of Maravai LifeSciences (NASDAQ: MRVI), is a CDMO that helps life science leaders and innovators overcome the challenges of synthesizing and scaling nucleic acids, NTP and mRNA styling analogs with unique scaling expertise and mRNA production capabilities, including its proprietary CleanCap® mRNA styling technology. TriLink continues to expand its cGMP and general manufacturing capability at its new global headquarters in San Diego, California to support the production of mRNA, oligonucleotides and plasmids for therapeutic, vaccine and diagnostic customers. www.trilinkbiotech.com

CLEANCAP® and TRILINK® are registered trademarks of TriLink Biotechnologies, LLC.

About Maravai LifeSciences Maravai is a leading life sciences company providing products essential to enable the development of drug therapies, diagnostics, new vaccines and to support research into human disease. The Maravai companies are leaders in providing nucleic acid synthesis and biosafety testing products and services to many of the world’s leading biopharmaceutical, vaccine, diagnostic, and cell and gene therapy companies. .

For more information on Maravai LifeSciences, visit www.maravai.com.

Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/new-england-biolabs-releases-next-generation-hiscribe-in-vitro-transcription-kit-incorporating-trilink-biotechnologies -cleancap -technology-for-synthesis-mrna-301418815.html

SOURCE New England Biolabs


Source link

Leave A Reply

Your email address will not be published.